On October 6, Allogene announced the initiation of the Phase II ALPHA2 trial of the investigational allogeneic CAR T therapy ALLO-501A for the treatment of
Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine -Primary and secondary endpoints of safety and immunogenicity met -Oral vaccine
On October 4, the U.S. Department of Health and Human Services (HHS) announced that it was purchasing roprostim from Amgen to respond to radiological and
On October 6, Provention announced an agreement with Sanofi to jointly advance the commercialization of teplizumab. Previously, the FDA has accepted a Biologics License Application
The University of Queensland in Australia has announced that a new study has revealed how COVID-19 affects the heart and how it differs from that
In a new study, an international team has identified 89 genetic loci associated with stroke risk and six genes that are potential drug targets for
On October 4, miRecule announced that it has entered into a strategic cooperation and exclusive license agreement with Sanofi to accelerate the development of “best-in-class”
On October 4, Pfizer announced that the oral PARP inhibitor Talzenna (talazoparib) combined with Xtandi (enzalutamide) in the treatment of male patients with metastatic castration-resistant
Transcriptome, proteome and metabolome, among these three omics, metabolome is considered to be the most difficult omics. Because of the many types of metabolites, the
Both mRNA vaccines and inactivated vaccines are autoimmune preparations made of bacteria, viruses and other pathogenic microorganisms and their metabolites through special preparation methods for
On October 3, Alexion, a subsidiary of AstraZeneca’s rare disease business, announced that it had reached a definitive acquisition agreement with Lexington. The acquisition is
On October 3, Incyte announced the acquisition of Villaris Therapeutics, which was invested and incubated by Medicxi, and acquired the latter’s anti-IL-15Rβ monoclonal antibody drug
